

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

**VOLUNTARY ANNOUNCEMENT RELATING TO
ESTABLISHMENT OF SEQUENCIO THERAPEUTICS COMPANY LIMITED
TO ADVANCE THERAPEUTIC CANCER VACCINES DEVELOPMENT**

CK Life Sciences Int'l. (Holdings) Inc. (the “Company”) announces the establishment of Sequencio Therapeutics Company Limited (“Sequencio”), a wholly-owned subsidiary of the Company dedicated to advancing the Company’s therapeutic cancer vaccine portfolio.

Sequencio has been established to consolidate the Company’s therapeutic cancer vaccine research and development portfolio under a dedicated organisation, reflecting the Company’s strategic focus on this emerging class of cancer immunotherapy. Sequencio is focused on the development of therapeutic cancer vaccines designed to train a patient’s own immune system to achieve durable, long-term remission with a favourable safety profile, addressing key limitations of current standard-of-care therapies. The establishment of Sequencio supports a long-term vision of shifting cancer treatment paradigms from transient tumour reduction toward sustained, immune-controlled remission, with vaccine discovery and design conducted in-house and development advanced through a combination of internal capabilities and external collaborations.

Sequencio’s preclinical portfolio includes the Company’s investigational cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (TROP2), which has demonstrated robust T-cell immune responses and achieved 100% tumour growth inhibition in preclinical breast and colorectal cancer mouse studies. The portfolio also includes vaccine candidates targeting PRAME (Preferentially Expressed Antigen in Melanoma), PD-L1 (programmed cell death ligand 1), B7-H3 (B7 homolog 3), and Claudin 6.

As previously announced, the Company completed a transaction in 2024 with Dogwood Therapeutics, Inc. (“Dogwood”), a Nasdaq-listed company that develops new treatments for pain and neuropathy, resulting in the Company acquiring a majority stake in Dogwood. In 2025, the Company’s late-stage melanoma vaccine, seviprotimut-L, was sold to TransCode Therapeutics, Inc. (“TransCode”), another Nasdaq-listed company, in exchange for an equity interest in TransCode.

With Sequencio, TransCode and Dogwood, the Company now offers an R&D platform with a diversified pipeline of early and late-stage projects targeting substantial unmet medical needs.

By Order of the Board
CK Life Sciences Int'l. (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 10 March 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Mr. Lance Richard Lee Yuen and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).